STOCK TITAN

BioLife Solutions (NASDAQ: BLFS) HR chief sells 241 shares under plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a small sale of company stock. On 01/06/2026, she sold 241 shares of Common Stock at a price of $25.59 per share, leaving her with 75,765 shares owned directly after the transaction.

According to the footnote, this sale was made under a Rule 10b5-1(c) trading plan that was adopted effective 01-03-2023. The filing explains that the trade was executed to satisfy tax withholding obligations related to the vesting of restricted stock rather than as a discretionary open-market sale.

Positive

  • None.

Negative

  • None.
Insider Aebersold Sarah
Role Chief Human Resources Officer
Sold 241 shs ($6K)
Type Security Shares Price Value
Sale Common Stock 241 $25.59 $6K
Holdings After Transaction: Common Stock — 75,765 shares (Direct)
Footnotes (1)
  1. [object Object]
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aebersold Sarah

(Last) (First) (Middle)
3303 MONTE VILLA PARKWAY
SUITE 310

(Street)
BOTHELL WA 98021

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Human Resources Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 S(1) 241 D $25.59 75,765 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Remarks:
/s/ Sarah Aebersold 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioLife Solutions (BLFS) report in this Form 4?

The Form 4 reports that Chief Human Resources Officer Sarah Aebersold sold 241 shares of BioLife Solutions Common Stock on 01/06/2026.

At what price were the BioLife Solutions (BLFS) shares sold and how many remain?

The 241 shares were sold at $25.59 per share. After this transaction, 75,765 shares of Common Stock are reported as beneficially owned directly.

Was the BioLife Solutions (BLFS) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a Rule 10b5-1(c) trading plan adopted by the reporting person effective 01-03-2023.

Why did Sarah Aebersold sell BioLife Solutions (BLFS) shares?

The footnote explains that the sale was executed to satisfy tax withholding obligations arising from the vesting of restricted stock.

What is Sarah Aebersold’s role at BioLife Solutions (BLFS)?

Sarah Aebersold is reported as an officer of BioLife Solutions Inc., serving as the Chief Human Resources Officer.

Is the ownership reported in this Form 4 direct or indirect?

The Form 4 indicates that the 75,765 shares held after the transaction are owned directly by the reporting person.